Haldor Topsøe remains the largest shareholder of cancer treatment developer IGM Biosciences, whose shares have risen more than 50% since it floated yesterday.
The developing digital health sector has had to wait almost three years for the public markets to open up to it, but when they did, it was corporate venturing portfolio companies that were first through the flotation exit doors.
Pfizer spinoff Springworks, which also counts GlaxoSmithKline as an investor, secured $162m in an initial public offering that followed $228m of funding.
Alphabet, Baidu, Microsoft and Qualcomm all notched up exits as the cloud services provider floated above a range that had already been increased.
Shin Nippon's migraine treatment spinoff, Satsuma Pharmaceuticals, floated above its range to raise $82.5m in an offering that follows $86m of funding.
The SoftBank-backed biological analysis technology provider priced its shares above its range and will likely close the offering at $449m.